北京时间2024年9月13日,生物科技股诺瓦瓦克斯医药(NVAX.US)在盘中出现大涨,股价最高上涨6.04%。分析人士认为,主要原因是该公司更新后的新冠疫苗获准在美国上市,市场对其在疫苗领域的前景重拾信心。
诺瓦瓦克斯医药宣布,其更新后的新冠疫苗已在美国上市,适用于12岁及以上人群,可用于预防最新变异病毒株感染。此前,该公司已在美国商业化了初版新冠疫苗。新加坡、澳大利亚、加拿大、欧洲等国家和地区也已批准上市。
尽管新冠疫情已远离高峰,但疫苗需求依然存在。诺瓦瓦克斯医药致力于保持新冠疫苗产品的更新迭代,顺应疫情发展形势,旨在让其疫苗在全球范围内继续发挥作用。与mRNA疫苗相比,诺瓦瓦克斯的产品无需低温冷藏,运输便利性较强。目前该公司正加紧扩大全球产能,以满足多国的需求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.